Pharm Co. Breckenridge Sues Rivals Over Generic Laxative

Law360, New York (November 2, 2011, 10:01 PM EDT) -- Breckenridge Pharmaceutical Inc. on Wednesday accused rival drugmakers UCB Inc. and Kremers Urban Pharmaceuticals Inc. of marketing prescription versions of Breckenridge's generic laxative product, despite a former agreement to stop distributing the drug.

In its complaint filed in New York federal court, Breckenridge alleges that even though UCB had obtained the U.S. Food and Drug Administration’s approval to market prescription laxative product Glycolax in 2004, it had entered into a superceding agreement with the FDA in June 2007 to stop distributing the drug from from December...
To view the full article, register now.




Case Information

Case Title

Breckenridge Pharmaceutical, Inc. v. UCB, Inc. et al

Case Number



New York Southern

Nature of Suit

Other Statutory Actions


Victor Marrero

Date Filed

November 1, 2011

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.